Transcript Powerpoint template for scientific posters (Swarthmore

SWGDRUG
Scientific Working Group for the Analysis of Seized Drugs
SWGDRUG Subcommittees
SWGDRUG History
1997: DEA and ONDCP co-sponsored formation of the
Technical Working Group for the Analysis of Seized
Drugs (TWGDRUG)
1999: Forensic scientists from the United States, England,
Canada, Australia, Japan, Germany, the Netherlands,
United Nations, international forensic organizations
and academia were invited to meet in Washington, DC.
 Education and Training
Revisions to SWGDRUG Recommendations:
 Editorial/Communications and Reporting
 Last public comment period regarding the proposed
Report Writing revisions ended September 2010.
 Uncertainty
 Comments from public were considered
 Clandestine Laboratory Analysis
 Glossary
 Current version: Version 5.1, 2011-01-27 contains
approved/revised recommendations from the working
group.
1999: SWGDRUG name adopted
SWGDRUG Document Development
2001: First edition of SWGDRUG Recommendations
approved
 Documents are drafted by sub-committee
 Drafts reviewed by core committee
 Drafts posted on website for public comments
SWGDRUG Mission
To recommend minimum standards for the
forensic examination of seized drugs and to
seek their international acceptance.
SWGDRUG Core Committee





















DEA – Scott Oulton (Chair)
DEA – Dr. Sandra Rodriguez-Cruz (Secretariat)*
FBI - Eileen Waninger (Pamela Reynolds)
ASCLD – Garth Glassburg
NIST – Susan Ballou (Karen Phinney)
ASTM and NEAFS – Jack Mario
Educator – Dr. Suzanne Bell
Educator – Dr. Eric Person
CAC & NWAFS – Jerry Massetti
MAFS – Richard Paulas
MAAFS – Linda Jackson
SAFS – Christian Matchett
SWAFS – Scott Vajdos
Toxicology – Dr. Robert Powers
Canada – Richard Laing
United Kingdom – Dr. Sylvia Burns
Australia – Catherine Quinn
Germany – Dr. Udo Zerell
ENFSI – Dr. Michael Bovens
UNODC – Dr. Iphigenia Naidis
AFSN/IDWG – Dr. Angeline Yap Tiong Whei
*non-voting
(at least 60 days)
 Drafts revised as needed
 Final documents voted on by core committee
as per SWGDRUG bylaws
Document Dissemination
SWGDRUG communicates work products via:
 WWW.SWGDRUG.COM
 Presentations at local, national and
international meetings
 Development of standards/best
practices/protocols utilizing a standards
development organization (SDO)
January 2011 Core Committee Meeting
Accomplishments:
 Approval of SWGDRUG Recommendations 5.1
 Implementation of SWGDRUG mass spectral library
 New document: Analysis of Clandestine Drug
Laboratory Evidence
 Revisions to Supplemental Document SD-3
 New survey (feedback mechanism) developed to
assess impact of SWGDRUG Recommendations
Report Writing, Section 9.2
Reports issued by laboratories shall be accurate, clear,
objective, and meet the requirements of the jurisdictions
served. These reports shall include the following information:













title of report
identity and location of the testing laboratory
unique case identifier (on each page)
clear identification of the end of the report (e.g., Page 3 of 3)
submitting agency
date of receipt of evidence
date of report
descriptive list of submitted evidence
identity and signature (or electronic equivalent) of analyst
results / conclusions
a list of analytical techniques employed
sampling
uncertainty.
If elements listed above are not included on the report, the
laboratory shall have documented reasons (i.e. specific
accreditation, customer or jurisdictional considerations), for
not doing so.
Part IIIA Sampling
6 Reporting
6.1 Statistically selected sample(s)
Reporting statistical inferences for a population is
acceptable when testing is performed on the statistically
selected units. The language in the report must make it
clear to the reader that the results are based on a sampling
plan.
6.2 Non-statistically selected sample(s)
The language in the report must make it clear to the reader
that the results apply to only the tested units. For example,
2 of 100 bags were analyzed and found to contain Cocaine.
SWGDRUG MS Library
 SWGDRUG has compiled a mass spectral library
from a variety of sources, containing drugs and
drug-related compounds
 All spectra collected using EI-MS systems
 DISCLAIMER: Although SWGDRUG makes an
effort to review the accuracy of spectra prior to
entry, this library should only be used as an
analytical tool.
 Use traceable reference materials to support
identifications of drugs
 SWGDRUG MS library is available in two formats:


NIST MSSEARCH program (free)
Agilent Technologies
 Currently contains 1371 compounds
 Library will be updated often to keep up with
emerging trends
SWGDRUG Supplemental Documents
 Intended to be a resource for those responsible for
implementing SWGDRUG Recommendations
 Not all inclusive; many ways to implement
Recommendations
 Purpose is to provide examples to be used in
conjunction with SWGRUG Recommendations
 Comments/suggestions from public considered
Current Supplemental Documents
 Supplemental Document SD-1:
A Code of Professional Practice for Drug Analysts
 Supplemental Document SD-2:
Quality Assurance/Validation of Analytical Methods
 Supplemental Document SD-3:
Examples of Measurement Uncertainty for Weight
Determinations
 Submissions from public are welcome
Seeking International Acceptance
 SWGDRUG has brought all of their recommendations
(except ethics) to the American Society for Testing and
Materials (ASTM)
 All SWGDRUG recommendations have been adopted
by ASTM and have become internationally recognized
standards/practices
 ASTM Standards:
 E2326-09
Standard Practice for Education and Training of
Seized-Drug Analysts
 E2327-10
Standard Practice for Quality Assurance of
Laboratories Performing Seized-Drug Analysis
 E2329-10
Standard Practice for Identification of Seized Drugs
 E2548-07
Standard Guide for Sampling Seized Drugs for
Qualitative and Quantitative Analysis
 Pending
Uncertainty Recommendations
Revisions to SD-3
New Document: Analysis of Clandestine
Drug Laboratory Evidence
 Developed in cooperation with Clandestine
Laboratory Investigating Chemists (CLIC)
 Draft recommendation approved for public comment
 This draft document was revised as a result of
input received from the community and
professional statisticians
 Further explains approach in regards to
correlations and assumptions
 Currently posted on website soliciting input
from forensic science community until April 15,
2011
 The comment period expires April 15, 2011
 Draft document provides guidance on the chemical
analysis of items and samples related to suspected
clandestine laboratories
Pending Supplemental Document
 SD-4 - Examples of Measurement Uncertainty
for Purity Determinations
Development of Training Program Outline
(Education and Training Subcommittee)
 SWGDRUG is working with ENFSI-DWG to
develop a training outline containing core
competencies
 To assess the value and utility of the SWGDRUG
recommendations in forensic science community
 Feedback document approved by core committee
(January 2011)
 Link on SWGDRUG website: www.surveymonkey.com
 Accepting feedback until June 30, 2011
SWGDRUG Website
2005-2010
 Contains several examples of estimating
measurement uncertainty for purity
determinations (e.g., bottom up, top down)
 Currently being drafted and expected to be
released for public comment by July 2011
 Anticipated completion by May 2011
2010: January – December
 Phase 1 - Provide resources to community
 Accessible via SWGDRUG website
 Will contain links to open source training programs
(i.e., VA Department of Forensic Science)
SWGDRUG Requests Feedback
www.swgdrug.org